Stifel Maintains Buy on Intellia Therapeutics, Lowers Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha maintains a Buy rating on Intellia Therapeutics but lowers the price target from $80 to $64.

September 11, 2024 | 11:44 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stifel analyst Dae Gon Ha maintains a Buy rating on Intellia Therapeutics but lowers the price target from $80 to $64, indicating a more cautious outlook.
The maintained Buy rating suggests continued confidence in Intellia's potential, but the lowered price target reflects a more cautious outlook, possibly due to market conditions or company performance. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100